BioMarin Pharmaceutical's Q4 revenue up 17%, beats expectations

BioMarin Pharmaceutical

23/02/2026 21:14

Overview

Biotechnology firm's Q4 revenue rose 17% yr/yr, beating analyst expectations

Adjusted EPS for Q4 missed analyst expectations

Outlook

BioMarin expects 2026 total revenues between $3.325 bln and $3.425 bln

Company anticipates 2026 Non-GAAP diluted EPS between $4.95 and $5.15

Result Drivers

VOXZOGO GROWTH - 31% revenue growth driven by new patient initiations and large government orders, especially in Latin America

ENZYME THERAPIES - 13% revenue growth due to increased patient demand and timing of government orders

Company press release: ID:nPnhCSVwa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$875 mln
$827.89 mln (24 Analysts)
Q4 Adjusted EPS
Miss
$0.46
$0.62 (18 Analysts)
Q4 EPS
-$0.24
Q4 Net Income
-$47 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for BioMarin Pharmaceutical Inc is $94.50, about 47.5% above its February 20 closing price of $64.08

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)